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Cerebrotendinous xanthomatosis (CTX) is a rare
autosomal recessive disease characterized by lipid
accumulation in several tissues, mainly in the eye len-
ses, central nervous system (CNS) and muscle ten-
dons. Mutations in the gene that codes for the he-
patic enzyme sterol 27-hydroxylase (CYP27A1) have
been found in these patients. We present the first
description of a Brazilian family with suggestive cli-
nical presentation and diagnosis confirmation thro-
ugh genetic test of CYP27A1 gene.
CASE
Case 1 – A 47 years old white man which symptoms
began at 20 years old (according to the mother’s informa-
tion). He presented progressive walking difficulty, becom-
ing unable to walk fast at 40 years old. Since the begin-
ning he presented cognitive difficulties and bilateral swel-
ling of Achilles tendons. He presented delay of the psy-
chomotor development and started walking by one year
and a half and he acquired the capacity to run and to go
up stairways just at five years of age. The mother refer-
red that he had a history of chronic diarrhea during the
childhood. She denied other family members with simi-
lar symptoms, except for the patient’s younger brother. 
Physical examination disclosed no abnormalities except
for bilateral swelling of Achilles tendons (Fig 1a). In the
neurological examination, he presented mild mental retar-
dation, incomprehensive disarthria, mild bilateral facial
palsy without other findings in cranial nerves. His mus-
cular strength was IV - in superior limbs (SL) and IV- in infe-
rior limbs (IL) according to Medical Research Council (MRC)
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ABSTRACT - Cerebrotendinous xanthomatosis is a treatable rare autossomal recessive disease characteri-
zed by lipid storage secondary to a sterol 27-hydroxylase deficiency in the formation of cholic and cheno-
deoxycholic acids. We describe two Brazilian brothers with cognitive impairement and chronic diarrhea.
One of them also presents bilateral cataracts. Neurological findings were progressive walking deficit, limb
ataxia and pyramidal signs. Both patients had bilateral Achilles tendon xanthomata. Magnetic resonance i-
mage showed signal alterations in cerebellar hemispheres. We describe these cases with molecular genetic
analysis confirming diagnosis and comparing with previous literature. The CYP27A1 gene study showed a
C1187T mutation on exon 6.
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Xantomatose cerebrotendínea: relato de dois irmãos brasileiros
RESUMO - Xantomatose cerebrotendínea é doença autossômica recessiva tratável causada pelo acúmulo
de lipídeos por deficiência da enzima 27-esterol hidroxilase na produção de ácido cólico e deoxicólico. Descreve-
mos dois irmãos brasileiros com dificuldade cognitiva e diarréia crônica. Um deles apresentava catarata bi-
lateral. Os achados neurológicos foram dificuldade progressiva para deambular, ataxia de membros e sinais
piramidais. Ambos tinham xantomas de tendão aquileu bilateralmente. O exame de ressonância magnéti-
ca revelou áreas de sinal hiperintenso em ambos os hemisférios cerebelares. Descrevemos os casos com diagnós-
tico genético comparando-os com a literatura. O estudo do gene CYP27A1 demonstrou a mutação C1183T no
exon 6.
PALAVRAS-CHAVE: xantomatose cerebrotendínea, 27-esterol hidroxilase, CYP27A1.
1086 Arq Neuropsiquiatr 2004;62(4)
Fig 1. Achilles tendon xanthomas (arrows): case 1 (A) and case 2 (B).
Fig 2. Brain MRI of the case 1 (A) [coronal T2WI sequence] and case 2 (B) [axial ‘Flair’ sequence]
showed hiperintense signal in both cerebellar hemispheres (arrows).
rating. We noted moderate spasticity in IL, preserved
trophism and increased deep tendon reflexes with bilate-
ral Babinski sign. The sensibility was preserved and there
was retraction in bilateral Aquilles tendon. The patient
presented symmetrical dismetry and disdiadococinesy in
SL. The cerebellar clinical evaluation of IL was disabled
by the limitation of the movements. He had also gait atax-
ia and walked with support.
Laboratorial exams (blood count, biochemistry, hepat-
ic and renal function, lipid analysis and coagulation tests)
were normal. The biochemical analysis for serum cholesta-
nol level, urinary bile alcohol excretion and chenodeoxy-
cholic acid in bile were not done. Cerebrospinal fluid (CSF)
was normal. Electrocardiogram (ECG) presented over-
load of left ventricle. Electroencephalogram (EEG) sho-
wed mild diffuse cerebral suffering, without irritation activ-
ity. Electrophisiologic studies showed sensorimotor
demyelinating polineuropathy with mild axonal charac-
teristics (Table 1). Ophthalmologic exam evidenced atro-
phy of retinal pigmented epithelium and peripapillar atro-
phy. Magnetic resonance imaging (MRI) showed hyper-
intense signal in the postero-inferior segments of both
cerebellar hemispheres on T2 WI and ‘FLAIR’ sequences
(Fig 2a). CYP27A1 gene was sequenced according to
standard and adequate techniques1. It showed homozy-
gous mutation in exon 6 (C1183T) of the CYP27A1 gene. 
Case 2 – A, 40 years old white man, case one´s broth-
er, which according to the mother’s information, present-
ed learning difficulty since childhood, unable to read or
to write. He did not finish the basic school. At 35 years of
age he began with progressive difficulty to walk and two
years after he began to present bilateral swellings of Achil-
les tendon. He also presented chronic diarrhea and was
submitted to a bilateral cataracts surgery in the childhood.
Physical examination disclosed no abnormalities ex-
cept for bilateral swellings of Achilles tendons (Fig 1b).
In the neurological exam he presented mild mental retar-
dation, moderate disarthria, visual handicap and facial
palsy without other abnormalities in cranial nerves. The
muscle strength was V in SL and IV+ in IL (MRC rating).
Other findings were spasticity in IL with preserved tro-
phism, increased deep tendon reflexes with bilateral Ba-
binski and Hoffman signs. Sensibility was preserved. He
had walking disturbance with ataxia and spasticity in IL. 
Laboratorial exams (blood count, biochemistry, lipid
analysis, hepatic and renal function) were normal. The
biochemical analysis for serum cholestanol level, urina-
ry bile alcohol excretion and chenodeoxycholic acid in
bile were not done. CSF presented mild elevation of pro-
teins (75mg/dl, reference: 35 to 45 mg/dl) with other valu-
es in normal limits. ECG presented overload of left came-
ras. EEG presented with mild diffuse cerebral suffering,
without irritation activity. Electrophisiologic studies
showed sensorimotor axonal polineuropathy with mild
demyelination (Table 1). He was submitted to a muscle
biopsy with normal fresh frozen section (HE-trichrome,
oil red O, PAS, cresyl violet and siryus red) and histochem-
ical reactions (ATPase, NADH, esterase, myophosphory-
lase, acid phosphatase, alkaline phosphatase, succinate
dehydrogenase, cytochrome-C oxidase and adenylate
deaminase). Ophthalmologic exam evidenced incipient
cataracts without surgical indication. MRI with hyper-
intense signal in inferior segments of both cerebellar
hemispheres on T2WI and ‘FLAIR’ (Fig 2b). Genetic analy-
sis showed homozygous mutation in exon 6 (C1183T) of
the CYP27A1 gene.
Mother’s blood was sequenced and she was a carrier
of the same exon 6 CYP27A1 gene mutation.
The DNA extraction was made in Curitiba by one au-
thor (SR) and the CYP27A1 analysis was made in Nijme-
gen, The Netherlands (EAS). In both cases we did not start
any treatment due to acquisition difficulty of medication
and loss of follow-up.
DISCUSSION
CTX was first described in two cousins, with
the presence of cerebellar and pyramidal signs, pa-
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late myoclonus, cognitive disability, cataracts and
tendon xanthomas, apud Bertini2. The main clin-
ical characteristics are cataracts and premature
atherosclerosis, tendon xanthomas with preferen-
tial location for the Achilles tendon and neurolog-
ical manifestations as pyramidal signs, cerebellar
ataxia, seizures, cognitive disability, dementia and
peripheral neuropathy1,3,4. The findings observed
in our patients were cataracts, tendon xanthomas
and neurological manifestations, such as cerebel-
lar ataxia, pyramidal signs, cognitive disability and
peripheral neuropathy suggesting CTX diagnosis.
The combination of chronic diarrhea and bilateral
cataracts in the childhood, described in the case 2,
was pathognomonic for the disease5. Besides cata-
racts, other retinal abnormalities have been descri-
bed in these patients as paleness of the optical disk
and senile retinal degeneration, as we could see in
the case 16.
Behavioral disturbance as depressed or distim-
ic humor, irritability, appetite reduction, insomnia
and fatigue can be present1,3,4. Heart complications,
as lipomatosis hipertrophy with atrial sept thickness
and lung alterations and osteoporosis were descri-
bed, none was found in our patients7-9.
Other manifestations have been described, such
as chronic myelopathy and spastic paraplegy in as-
sociation with frontal lobe dementia. The differen-
tial diagnosis must be done in patients with early-
onset parkinsonism-plus, that usually is associated
Table 1. Nerve conduction study.
Nerve Variable response Case 1 Case 2 N Nerve Variable response Case 1 Case 2 N
Median S Amplitude (µV) * * >15 Median M D-Amplitude (mV) 10.5 14.0 >5.0
Latency (ms) * * <3 P-Amplitude (mV) 9.73 15.0 >5.0
CV(m/s) * * >49 D-Latency (ms) 5.16 3.66 <4.2
Ulnar S Amplitude (µV) * * >15 CV (m/s) 49.5 46.9 >50
Latency (ms) * * <3 F wave  (ms) 32.2 28.0 <31
CV (m/s) * * >49 Ulnar M D-Amplitude (mV) 9.67 11.1 >5.0
Sural Amplitude (µV) NP NP >6 P-Amplitude (mV) 9.0 10.6 >5.0
Latency (ms) NP NP <3 D-Latency (ms) 5.04 3.3 <3.4
CV(m/s) NP NP >40 CV (m/s) 51.5 49.0 >50
Radial S Amplitude (µV) 51.3 35.5 >12 Perineal M D-Amplitude (mV) 2.27 NP >4.0
Latency (ms) 2.0 2.12 <2.1 P-Amplitude (mV) 1.55 NP >4.0
CV(m/s) 50.0 47.2 >50 D-Latency (ms) 7.30 NP <5.6
CV (m/s) 27.4 NP >40
PoTibial M D-Amplitude (mV) 3.33 5.53 >5.0
P-Amplitude (mV) 1.13 2.13 >5.0
D-Latency (ms) 8.5 5.64 <6.0
CV(m/s) 29.8 31.5 >40
* no patient collaboration; CV, conduction velocity; S, sensory; M, motor; Po, posterior; D, distal; P, proximal; NP, no potentials; N, normal.
Needle electromyography was normal in Case 1 and showed chronic denervation in Case 2. 
with walking disturbances, pyramidal signs, cogni-
tive abnormalities and partial L-dopa response10-12.
The diagnosis can be confirmed by biochemi-
cal exams, which demonstrate increase of serum cho-
lestanol level and urinary bile alcohol excretion
associated with reduction of the chenodeoxycholic
acid in bile13. Because technical difficulties these tes-
ts were not done in our patients.
Molecular genetic analysis, accomplished in our
patients, is obtained by the screening of CYP27A1
gene located in chromosome 2q 23. The genomic
structure of CYP27A1 contains nine exons and eight
introns with 18,6 kb of DNA. The mature enzyme
consists of 498 amino acids and it is expressed in CNS,
liver, lungs, duodenum and endothelial cells. Until
now, more than 45 mutations were described in the
CYP27A1 gene, usually affecting heme or adreno-
doxin related domains between exons 6 and 91,13-15.
The patients described here presented a homozy-
gous CYP27A1 gene mutation in exon 6 (1183 C>T)
that was already described in other populations1,16.
CYP27A1 enzyme (sterol 27-hydroxylase) with
two protein cofactors, adrenodoxin and adrenodo-
xin reductase, hydroxylates a variety of sterols at
the C-27 position producing the primary bile acids
(cholic and chenodeoxycholic acid)14. In normal in-
dividuals, the primary bile acid inhibits the rate-
limiting step in their production, the enzyme 7 µ-
hydroxylase (negative feedback mechanism). The
gene mutation causes deficiency of the enzyme ste-
1088 Arq Neuropsiquiatr 2004;62(4)
rol 27-hydroxylase, leading to reduced synthesis of
cholic acid and almost no chenodeoxycholic acid. Due
to the absence of the negative feedback mecha-
nism, the 7 ?-hydroxylase activity is increased, pro-
ducing excessive cholesterol and cholestanol and
accumulating them in many tissues with increased
urine excretion of the bile alcohols2,17. The metabo-
lic pathway can be seen in the Figure 3.
The electrophisiologic findings from CTX patients
usually show an axonal degeneration, but they com-
monly are described as a mixed neuropathy, as ob-
served in our cases1. Muscle biopsy is uncharacteris-
tic4.Xanthomatous lesions, lipid crystal clefts and
macrophage clusters that are usually seen in the
CNS, were not found in the muscle biopsies4. MRI
usually demonstrate hyperintense signal in T2 and
FLAIR located preferentially in periventricular area,
basal ganglia and dentate nuclei of the cerebel-
lum, besides variable degrees of cerebral and cere-
bellar atrophy (Fig 2A)18-21. Brain spectroscopy de-
monstrates significant decreases of NAA (N-acety-
laspartate) and increases of lactate MRI signals.
These results suggests a brain accumulation of me-
tabolic neurotoxins and deficiency of the mitochon-
dria metabolism secondary to the high levels of cho-
lestanol and bile alcohols21,22.
The mechanism for neurological manifestations
is not known. A hypothesis suggests that this hap-
pens from an increase neuronal apoptosis caused by
the cholestanol overload. The presence of apolipo-
protein B in CSF indicates penetration of low-den-
sity lipoprotein particles from plasma through the
blood-brain barrier. These lipoprotein particles may
carry cholestanol as well as cholesterol13. Chenodeo-
xycholic acid replacement therapy is usually asso-
ciated with improvement in the clinical symptoms,
normalization cholesterol synthesis and reestablish-
ment of selective permeability of blood-brain bar-
rier with normalized CSF apolipoprotein and sterol
concentrations23. The absence of neurological dys-
function in other lipid disorders (familial hypercho-
lesterolemia or sitosterolemia) further support the
hypothesis that cholestanol itself impairs brain
function13.
It is important to remember that precocious diag-
nosis is fundamental due to the good response with
chenodeoxycholic acid treatment reducing choles-
tanol accumulation and promoting lesion regres-
sion. The effectiveness of statins is controversial wi-
th the possibility of worsening the condition own-
ing to increased low-density lipoprotein uptake as
the result of augmented low-density lipoprotein
Fig 3. Enzymatic mechanism in Cerebrotendinous xanthomato-
sis (modified from reference 13). HMGCoA: 3-hydroxy 3-methyl-
glutaryl CoA; gray arrow: hyperactive pathway on the sterol
27- hydroxylase deficiency (crossed arrow) causing negative feed-
back reduction by bile acids over the enzyme 7 α-hydroxylase).
receptor activity13. The detection of the specific
mutation in each family is important to definitely
confirm the diagnosis, to start treatment as earli-
er as possible, and to provide accurate genetic coun-
seling to the patients and their family.
Acknowledgements - The authors wish to thanks
Dr. Ana C. Bacelar Limeira from CETAC - Curitiba for neu-
roimage evaluation.
REFERENCES
1. Verrips A, Hoesfloot LH, Steenbergen GCH, et al. Clinical and molecu-
lar genetic characteristics of patients with cerebrotendinous xanthomato-
sis. Brain 2000;123:908-919.
2. Bertini E, Dionisi-Vici C, Zeviani M. Metabolic and mitochondrial ataxi-
as. In Pulst SM (ed). Genetics of movement disorders. San Diego:
Elsevier,2003:238.
3. Lee Y, Lin PY, Chiu NM, Chang WN, Wen JK. Cerebrotendinous xantho-
matosis with psychiatric disorders: report of three siblings and litera-
ture review. Chang Gung Med J 2002;25:334-340.
4. Verrips A, van Engelen BGM, ter Laak H, et al. Cerebrotendinous xan-
thomatosis: controversies about nerve and muscle: observations in ten
patients. Neuromusc Disord 2000;10:407-414.
5. Cruysberg JRM, Wevers RA, Tolboom JJM. Juvenile cataract associa-
ted with chronic diarrhea in pediatric cerebrotendinous xanthomato-
sis. Am J Ophthalm 1991;112:606-607.
6. Dotti MT, Rufa A, Federico A. Cerebrotendinous xanthomatosis: hete-
rogeneity of clinical phenotype with evidence of previously undescri-
bed ophthalmological findings. J Inherit Metab Dis 2001;24:696-706.
7. Kawabata M, Kuriyama M, Mori S, Sakashita I, Osame M. Pulmonary
manifestations in cerebrotendinous xanthomatosis. Intern Med
1998;37:922-926.
8. Dotti MT, Mondillo S, Plewnia K, Agricola E, Federico A. Cerebroten-
dinous xanthomatosis: evidence of lipomatous hypertrophy of the atri-
al septum. J Neurol 1998;245:723-726.
9. Berginer VM, Shany S, Alkalay D, et al. Osteoporosis and increased bone
fractures in cerebrotendinous xanthomatosis. Metabolism 1993;42:69-74.
Arq Neuropsiquiatr 2004;62(4) 1089
10. Verrips A, Nijeholt GJ, Barkhof F, et al. Spinal xanthomatosis: a variant
of cerebrotendinous xanthomatosis. Brain 1999;122:1589-1595.
11. Sugama S, Kimura A, Chen W, et al. Frontal lobe dementia with abnor-
mal cholesterol metabolism and heterozygous mutation in sterol 27-
hydroxylase gene (CYP27). J Inherit Metab Dis 2001;24:379-392.
12. Grandas F, Anaya F. Early-onset parkinsonism in cerebrotendineous xan-
thomatosis. Mov Disord 2002;17:1396-1397
13. Moghadasian MH, Salen G, Frohlich JJ, Scudamore CH. Cerebrotendi-
nous xanthomatosis: a rare disease with diverse manifestations: arch
Neurol 2002;59:527-529.
14. Cali JJ, Russell DW. Characterization of the human sterol 27-hydroxyla-
se: a mitochondrial P-450 that catalyzes multiple oxidation reactions
in bile acid biosynthesis. J Biol Chem 1991;266:7774-7778.
15. Lamon-Fava S, Schaefer EJ, Garuti R, Salen G, Calandra S. Two novel
mutations in the sterol 27-hydroxylase gene causing cerebrotendinous
xanthomatosis. Clin Genet 2002;61:185-191.
16. Cali JJ, Hsieh CL, Francke U, Russell DW. Mutations in the bile acid
biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous
xanthomatosis. J Biol Chem 1991;266:7779-7783.
17. Oftebro H, Björkhem I, Stormer FC, Pedersen JL. Cerebrotendinous xan-
thomatosis: defective liver mitochondrial hydroxylation of chemode-
oxycholic acid precursors. J Lipid Res 1981;22:632-640.
18. Dotti MT, Federico A, Signorini E, et al. Cerebrotendinous xanthomato-
sis (van Bogaert-Scherer-Epstein disease): CT and MR findings. AJNR
1994;15:1721-1726.
19. Hokezu Y, Kuriyama M, Kubota R, Nakagawa M, Fujiyama J, Osame
M. Cerebrotendinous xanthomatosis: cranial CT and MRI studies in eight
patients. Neuroradiology 1992;34:308-312.
20. Vanrietvelde F, Lemmerling M, Mespreuve M, Crevits L, De Reuck J,
Kunnen M. MRI of the brain in cerebrotendinous xanthomatosis (van
Bogaert-Scherer-Epstein disease). Eur Radiol 2000;10:576-578.
21. De Stefano N, Dotti M, Mortilla M, Frederico A. Magnetic resonance
imaging and spectroscopic changes in brains of patients with cerebroten-
dinous xanthomatosis. Brain 2000;124:121-131.
22. Soffer D, Benharroch D, Berginer V. The neuropathology of cerebrotendi-
nous xanthomatosis revisited: a case report and review of the literatu-
re. Acta Neuropathol (Berl) 1995;90:213-220.
23. Salen G, Berginer V, Shore V, et al. Increased concentrations of choles-
tanol and apolipoprotein B in cerebrospinal fluid of patients with
cerebrotendinous xanthomatosis: effect of chenodeoxycholic acid. N Engl
J Med 1987;316:1233-1238.
